On Monday, Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s shares declined -1.72% to $2.29.
Amarin Corporation plc (ADR) (AMRN) and Walk with a Doc, a national nonprofit organization, recently declared a 2015 partnership to expand the reach of their national health awareness efforts.
Walk with a Doc is a free participation, year-round walking program held in communities across the United States and abroad. The program is dedicated to encouraging healthy physical activity in people of all ages with the aim of reversing the consequences of a sedentary lifestyle and improving health and well-being. Each walk is hosted by local physicians in public spaces and everyone is welcome.
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’s shares dropped -1.72% to $0.630.
AEterna Zentaris Inc. (USA) (AEZS) declared that it has filed an application for a patent (European Patent Office precedingity application: EP15000132) on a novel method of manufacturing zoptarelin doxorubicin, its hybrid cytotoxic molecule that is the subject of a pivotal ZoptEC Phase 3 clinical study in women with advanced, recurrent or metastatic endometrial cancer who have progressed and who have received one chemotherapeutic regimen with platinum and taxane (either as adjuvant or first-line treatment). The claimed manufacturing process is predictable to result in a noteworthy reduction in the cost of goods sold, providing a stronger competitive position for the Company.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The companys product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
At the end of Monday’s trade, Infosys Ltd ADR (NYSE:INFY)‘s shares dipped -1.65% to $34.52.
Infosys Ltd ADR (INFY) will declare the results for its fourth quarter and year ended March 31, 2015 on Friday, April 24, 2015 at 1:15 p.m. Indian Standard Time (IST) ( 3:45 a.m. US ET; 00:45 a.m. PST ; 8:45 a.m. London time; 3:45 p.m. Singapore / Hong Kong time) from its Chennai Development Center. The results will also be accessible on http://www.infosys.com.
Infosys Limited provides business consulting, technology, engineering, and outsourcing services worldwide. Its solutions comprise business IT services comprising application development and maintenance, independent validation services, infrastructure administration, business process administration, and engineering services compriseing of product engineering and life cycle solutions; and consulting and systems integration services, counting consulting, enterprise solutions, systems integration, and advanced technologies.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ended its Monday’s trading session with -1.63% loss, and closed at $1.81.
AVEO Pharmaceuticals, Inc. (AVEO) declared the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly raised plasma GDF15 levels. The data were presented in a poster titled “Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody” at the 2015 Annual Meeting of the American Association of Cancer Research in Philadelphia from April 18-22.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
